Heidi Steinfeldt

1.4k total citations
10 papers, 1.1k citations indexed

About

Heidi Steinfeldt is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Heidi Steinfeldt has authored 10 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 3 papers in Pulmonary and Respiratory Medicine and 3 papers in Oncology. Recurrent topics in Heidi Steinfeldt's work include Angiogenesis and VEGF in Cancer (5 papers), Renal cell carcinoma treatment (3 papers) and Cancer therapeutics and mechanisms (2 papers). Heidi Steinfeldt is often cited by papers focused on Angiogenesis and VEGF in Cancer (5 papers), Renal cell carcinoma treatment (3 papers) and Cancer therapeutics and mechanisms (2 papers). Heidi Steinfeldt collaborates with scholars based in United States, United Kingdom and Spain. Heidi Steinfeldt's co-authors include Steven D. Reich, George Wilding, Yazdi K. Pithavala, Roy S. Herbst, Hope S. Rugo, John W. Park, Glenn Liu, Merrill S. Kies, James L. Freddo and Christopher J. Jones and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Heidi Steinfeldt

10 papers receiving 1.1k citations

Peers

Heidi Steinfeldt

ONCOL

PRM

RNMI

Maja J.A. de Jonge Netherlands

Gregory Friberg United States

L Rhoda Molife United Kingdom

Erica Rappold United States

M. Wolf Germany

Alexander C. Klimowicz Canada

Lynda Grinsted United Kingdom

Angelica Fasolo Italy

Jacqui Rowbottom United Kingdom

Giorgia Migliardi Italy

Maja J.A. de Jonge Netherlands

Heidi Steinfeldt

865 ×1.2

848 ×1.4

ONCOL

420 ×1.0

PRM

259 ×1.0

70 ×0.5

RNMI

Citations per year, relative to Heidi Steinfeldt Heidi Steinfeldt (= 1×) peers Maja J.A. de Jonge

Countries citing papers authored by Heidi Steinfeldt

Since Specialization

Citations

This map shows the geographic impact of Heidi Steinfeldt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Steinfeldt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Steinfeldt more than expected).

Fields of papers citing papers by Heidi Steinfeldt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Steinfeldt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Steinfeldt. The network helps show where Heidi Steinfeldt may publish in the future.

Co-authorship network of co-authors of Heidi Steinfeldt

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Steinfeldt. A scholar is included among the top collaborators of Heidi Steinfeldt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Steinfeldt. Heidi Steinfeldt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Plummer, Ruth, Christopher J. Jones, Mark R. Middleton, et al.. (2008). Phase I Study of the Poly(ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors. Clinical Cancer Research. 14(23). 7917–7923. 298 indexed citations

Pacey, Simon, Richard H. Wilson, Mike Walton, et al.. (2007). A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors. Molecular Cancer Therapeutics. 6. 2 indexed citations

Giles, Francis J., William Bellamy, Zeev Estrov, et al.. (2005). The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leukemia Research. 30(7). 801–811. 38 indexed citations

Plummer, Ruth, Mark R. Middleton, R. Wilson, et al.. (2005). First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3065–3065. 37 indexed citations

Rugo, Hope S., Roy S. Herbst, Glenn Liu, et al.. (2005). Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results. Journal of Clinical Oncology. 23(24). 5474–5483. 410 indexed citations

Liu, Glenn, Hope S. Rugo, George Wilding, et al.. (2005). Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study. Journal of Clinical Oncology. 23(24). 5464–5473. 202 indexed citations

Rini, Brian I., Olivier Rixe, Ronald M. Bukowski, et al.. (2005). AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a Phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Journal of Clinical Oncology. 23(16_suppl). 4509–4509. 112 indexed citations

Rugo, H. S., Roy S. Herbst, Guoqiang Liu, et al.. (2004). Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2503–2503. 13 indexed citations

Giles, Francis J., Heidi Steinfeldt, William Bellamy, et al.. (2004). Phase 2 Study of the Anti-Angiogenesis Agent AG-013736 in Patients with Poor Prognosis Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).. Blood. 104(11). 1813–1813. 4 indexed citations

10.

Rugo, Hope S., Roy S. Herbst, Guoqiang Liu, et al.. (2004). Clinical and dynamic imaging results of the first phase I study of AG–013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 2503–2503. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact